DOCS N Stock Overview
Designs, develops, procures, markets, sells, and distributes footwear under the Dr.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Dr. Martens plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£29.87 |
| 52 Week High | UK£29.87 |
| 52 Week Low | UK£29.87 |
| Beta | 0.10 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -76.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| DOCS N | MX Luxury | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how DOCS N performed against the MX Luxury industry.
Return vs Market: Insufficient data to determine how DOCS N performed against the MX Market.
Price Volatility
| DOCS N volatility | |
|---|---|
| DOCS N Average Weekly Movement | n/a |
| Luxury Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: DOCS N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DOCS N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1945 | 2,591 | Kenny Wilson | www.drmartensplc.com |
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It offers originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name.
Dr. Martens plc Fundamentals Summary
| DOCS N fundamental statistics | |
|---|---|
| Market cap | Mex$27.91b |
| Earnings (TTM) | Mex$2.80b |
| Revenue (TTM) | Mex$21.74b |
10.0x
P/E Ratio1.3x
P/S RatioIs DOCS N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DOCS N income statement (TTM) | |
|---|---|
| Revenue | UK£1.00b |
| Cost of Revenue | UK£382.20m |
| Gross Profit | UK£618.10m |
| Other Expenses | UK£489.20m |
| Earnings | UK£128.90m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
Nov 30, 2023
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 61.79% |
| Net Profit Margin | 12.89% |
| Debt/Equity Ratio | 72.6% |
How did DOCS N perform over the long term?
See historical performance and comparison